A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Kirsch, MD, PhD
Princess Margaret Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chris O'Brien Hospital
Camperdown, New South Wales, Australia
- Princess Alexandra Hospital
Brisbane, Queensland, Australia
- Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
- Mcgill University Health Centre
Montreal, Quebec, Canada
- Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, MI, Italy
- University of California Los Angeles
Los Angeles, California, United States
- Mayo Clinic- Florida
Jacksonville, Florida, United States
- University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States
- University of Kansas Medical Center
Kansas City, Kansas, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Washington University
St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Duke University
Durham, North Carolina, United States
- the Ohio State University
Columbus, Ohio, United States
- Oregon Health & Science University
Portland, Oregon, United States
- University of Pennsylvania- Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pittsburgh (upmc Hillman Cancer Center)
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Jul 2017
- Primary completion
- 1 Sept 2025
- Completion
- 1 Sept 2028
- Last update posted
- 18 Nov 2023
- Registered enrollment
- 126
- Registry id
- NCT03092323
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.